The Liver Meeting 2026
Scientific Program Committee Disclosure List

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for Integrity and Independence in Accredited Continuing Education. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

TLM 2026 TLM Scientific Program Committee	
Saul J. Karpen, MD, PhD, FAASLD	*Scientific Consultant/Advisor:* Mirum, Intercept, Ipsen, Vertex, HemoShear
Janice Jou, MD, MHS, FAASLD	*Grant/Research Support:* Gilead
Michael R. Lucey, MD, FAASLD	*Scientific Consultant/Advisor:* Novartis*; Grant/Research Support: PharmaSolutions, Intercept Pharma, Exact Sciences*
Rotonya M. Carr, MD, FACP, FAASLD	*Scientific Consultant/Advisor:* Novo Nordisk, Madrigal, Intercept, Boehringer-Ingelheim*; Expert Testimony: McCarter & English, LLP; Grant/Research Support: Merck, ContextVision*
Scott Springer, PA-C, MPAS	*Scientific Consultant/Advisor: Ipsen, Salix, GlaxoSmithKline, Mirum; Grant/Research Support: AbbVie, Gilead*
Heather M. Patton, MD, FAASLD	*Nothing to Disclose*
Lorna M. Dove, MD, MPH	*Nothing to Disclose*
Adnan Said, MD, MS, FAASLD	*Scientific Consultant/Advisor:* Madrigal, Novo Nordisk*; Grant/Research Support: EXACT Sciences, Boehringer Ingelheim; Speakers' Bureau: Mallinckrodt*
Ramesh Batra, MD, MA(Bioethics), FRCS	*Scientific Consultant/Advisor:* Caredx Inc.
Mazen Noureddin, MD, , MHSc, FAASLD	*Scientific Consultant/Advisor:* Akero, Altimmune, Alligos, AstraZeneca, BI, Boston Pharma, Curve bioscience, Cytodyn, GSK, Histoindex, Kryia , Lilly, Madrigal, Merck, Novo Nordisk, OPKO, Rivus, Sagimet, Terns and Takeda*; Consulting for Equity: Rivus Pharma, OPKO, Kryia and Akero; Grant/Research Support: Allergan, Altimmune, Akero, BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit, GSK, Kowa, Enanta, Madrigal, Lilly, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking and Zydus*
Saikiran Kilaru, MD	*Nothing to Disclose*
Alexander Kuo, MD, FAASLD	*Grant/Research Support:* Grifols Therapeutics, AstraZeneca, Sequana Medical, Durect Corp, Intercept
Uchenna Agbim, MD	*Nothing to Disclose*

Samar H. Ibrahim, MBCHB, FAASLD	*Scientific Consultant/Advisor* : Alberio Pharma, Mirum pharmaceuticals
Staff:	
Steven Folstein, MFA M.Ed.	*Nothing to Disclose*
Laura Shelters, MS, Ed.	*Nothing to Disclose*